

REGENICIN, INC.

FORM 8-K (Current report filing)

Filed 04/20/11 for the Period Ending 04/11/11

Address	10 HIGH COURT LITTLE FALLS, NJ 07424
Telephone	646-403-3581
CIK	0001412659
Symbol	RGIN
SIC Code	3564 - Industrial and Commercial Fans and Blowers and Air Purification Equipment
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	09/30

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 11, 2011

REGENICIN, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation)

333-146834
(Commission File Number)

27-3083341
(I.R.S. Employer Identification No.)

10 High Court, Little Falls, NJ 07424
Address of principal executive offices

Registrant's telephone number, including area code: (973) 557-8914

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Section 8 – Other Events

Item 8.01 Other Events

On April 11, 2011, we received a letter from Lonza America Inc., alleging that we were in breach of our Know-How License and Stock Purchase Agreement (the “Agreement”) with Lonza Walkersville, Inc. The letter identified a past due payment to Lonza of \$183,687.42 and the unauthorized use of the trade name “PermaDerm”™.

In a letter dated April 14, 2011, we responded to Lonza by clarifying that we are current in payments due and even believe there had been a surplus paid to Lonza of approximately \$17,000. In addition, we further pointed out confusion relating to the ownership of trade name PermaDerm™ and our conclusion that the Agreement does not require Lonza’s consent of Regenicin's use of the trade name. We have asked Lonza for a meeting and hope to have this disagreement resolved through further discussions in the near future.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENICIN, INC.

/s/ Randall McCoy
Randall McCoy
CEO and Director
Date: April 20, 2011